{"preliminary_commentary":{"by_channel":{"podcast":5,"youtube":4,"x_thread":2},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT05920356\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"name":"CodeBreaK 202","nct_id":"NCT05920356","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=codebreak-202-nct05920356. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1250,"size":"standard","size_rule":"Standard: 151–300 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"Sotorasib administered in combination with carboplatin and pemetrexed.","label":"Sotorasib combined with carboplatin and pemetrexed","type":"EXPERIMENTAL"},{"description":"Pembrolizumab administered in combination with carboplatin and pemetrexed.","label":"Pembrolizumab combined with carboplatin and pemetrexed","type":"ACTIVE_COMPARATOR"}],"collaborators":[],"completion_date":{"date":"2032-06-29","type":"ESTIMATED"},"conditions":["Non-Small Cell Lung Cancer (NSCLC)"],"enrollment":{"count":750,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"Sotorasib","otherNames":["AMG 510","LUMYKRAS ®","LUMAKRAS ®"],"type":"DRUG"},{"name":"Pembrolizumab","otherNames":[],"type":"DRUG"}],"last_update":"2026-10-13","lead_sponsor":"Amgen","official_title":"A Phase 3, Multicenter, Randomized, Open-label Study Evaluating Efficacy of Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Subjects With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers, Negative for PD-L1, and Positive for KRAS p.G12C (CodeBreaK 202)","overall_status":"RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2027-06-30","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Progression-free Survival (PFS)","timeFrame":"Approximately 2.5 years"},{"measure":"Overall Survival (OS)","timeFrame":"Approximately 2.5 years"}],"references":[],"start_date":{"date":"2023-11-16","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)","url":"https://clinicaltrials.gov/study/NCT05920356"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/codebreak-202-nct05920356"}